Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for CNS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for CNS and 80,000+ other tickers.
See exactly how CNS's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CNS and 80,000+ other tickers.
Cohen & Steers, Inc. operates as a publicly traded holding company specializing in asset management. Through its various operating units, the firm delivers financial services to institutional investors, such as pension funds, university endowments, and charitable foundations. Its subsidiaries are tasked with managing bespoke client portfolios across equities, fixed income, multi-asset strategies, and commodities. Additionally, these subsidiaries develop and oversee a diverse range of investment vehicles, including mutual funds (focused on equity, fixed income, balanced, and multi-asset…
[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve
ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology and Phase 2 Clinical Pipelines at BIO-Europe 2026PR NewswireSEOUL, South Ko
Cohen & Steers generated $1.6 billion in third-quarter net inflows. The institutional pipeline reached $1.9 billion.
PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations or other uncommon EGFR mutations and active central nervous system (CNS) metastases. The data will be.
Schwab US Dividend Equity ETF has outperformed SPY YTD, up over 25% versus SPY's ~12%. SCHD's top holdings, including DINO, APA, and TXN, have delivered strong double- and triple-digit returns, driving ETF performance. Dividend growth remains robust, with eight SCHD constituents announcing increases averaging 5.73%, supporting the ETF's income appeal.